Research
Early gene expression changes with rush immunotherapy
-
* Corresponding author: Laurie S Davis laurie.davis@utsouthwestern.edu
1 Department of Internal Medicine, Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8884, USA
2 Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-8859, USA
Clinical and Molecular Allergy 2011, 9:12 doi:10.1186/1476-7961-9-12
Published: 30 September 2011Additional files
Additional file 1:
Table S1: PBMC display differentially expressed genes during RIT. An excel (.xls) spreadsheet depicts the expressed genes identified by Ingenuity Pathway Analysis that were derived from the 507 transcripts (≥1.5 fold change) sorted by biological function and including the p-value and a description of the molecule as well as the cellular localization.
Format: XLS Size: 106KB Download file
This file can be viewed with: Microsoft Excel Viewer
Additional file 2:
Figure S1: Basophil FcεRI expression is modulated by omalizumab. Basophil FcεRI expression (gated as Lineage-1-, HLA-DR+ and CD123+) is displayed as histograms for two experiments (A and B). Isotype control antibody binding is shown for two asthma patients (tinted histogram with gray lines) with similar results for healthy donors (not shown). Basophil FcεRI expression is shown for healthy donors (gray line) as controls and asthma patients on omalizumab for at least 3 months (black line).
Format: PPT Size: 115KB Download file
This file can be viewed with: Microsoft PowerPoint Viewer